World Immunotherapy Congress


2-5 November 2020 | Live Digital



1-2-1 Meetings
Co-located events

Sessions You Can't Miss



Current state of combination therapies including PD-1 checkpoint inhibitors

•A cross sectional study of published clinical trials showed that more than 80% of combination trials including a PD-1 checkpoint inhibitor increased activity compared to PD-1 monotherapy in the same indication
•This remarkable success is largely due to additive effects of independent combination agents
• Clinical synergy is not common in PD-1 combination trials, and is more evident for chemo and targeted therapies than for evolving immune oncology agents

Emmett Schmidt, Associate Vice President, Clinical Research, Oncology, MSD

Management of toxicities associated with immuno-oncology therapies. Have we made progress?

• Current Clinical Practice Guidelines (e.g. ESMO and ASCO)
• Evolving treatment paradigms
• Explorative approaches: early recognition and detection of risk factors

Céline Adessi , Senior Director & Group Head of Oncology and Clinical Safety Science , Roche

Integrating complex biomarkers to predict response and understand resistance to cancer immunotherapy agents

• To date, no single biomarker has proven effective at predicting response to immunotherapy
• Integration of complex biomarker signatures will likely be required for accurate prediction
• Data from multi-parameter assays also inform on disease biology and mechanisms of resistance

Philip Beer , Visiting Scientist/Consultant Genomicist , Sanger Institute/NHS

Festibval of Biologics


There are two parts to the Festival of Biologics: three conferences covering Antibodies, Immunotherapy, Biosimilars and an exhibition featuring solutions for pharma and biotech.